Novartis Keeps FY 2026 Net Sales Growth At Low Single-Digit, Raises Core Operating Income Outlook To In Line To Low Single-Digit Growth
Full-year 2026 guidance raised for core operating income o Net sales expected to grow low single-digit (unchanged) o Core operating income expected to be in line to grow low single-digit (from decline low single-digit)
Novartis says its medicine sales will grow slowly next year, staying flat overall. But the company expects to make more profit from those sales, which is better news than before.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.